Details
Stereochemistry | ACHIRAL |
Molecular Formula | CH5N3.CHNS |
Molecular Weight | 118.161 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
SC#N.NC(N)=N
InChI
InChIKey=ZJYYHGLJYGJLLN-UHFFFAOYSA-N
InChI=1S/CH5N3.CHNS/c2-1(3)4;2-1-3/h(H5,2,3,4);3H
Molecular Formula | CHNS |
Molecular Weight | 59.09 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | CH5N3 |
Molecular Weight | 59.0705 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Guanidine is a small basic compound. Guanidine stimulates the neuromuscular junction presynaptically by inhibiting voltage-gated potassium (Kv) channels, leading to the enhanced release of acetylcholine in the synaptic cleft. This stimulatory effect of guanidine underlies its use in the therapy for the neuromuscular diseases. The hydrochloride salt of guanidine was approved by FDA for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10973602
Curator's Comment: The study was performed on rats.
Originator
Sources: https://d-nb.info/1059797615/34
Curator's Comment: Original article: A. Strecker, Liebigs Ann. Chem. 1861, 118, 151-177.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2362996 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21926190 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | GUANIDINE HYDROCHLORIDE Approved UseGuanidine is indicated for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert. It is not indicated for treating myasthenia gravis. The Eaton-Lambert syndrome is ordinarily differentiated from myasthenia gravis by the usual association of the syndrome with small cell carcinoma of the lung, but myography may be necessary to make the diagnosis. Launch Date-9.5463362E11 |
PubMed
Title | Date | PubMed |
---|---|---|
Expression and refolding of full-length human TIMP-1. | 2001 |
|
Evolution and physiological roles of phosphagen systems. | 2001 |
|
Stabilization of hen egg white lysozyme by a cavity-filling mutation. | 2001 Feb |
|
[Discovery of cis-preference of aromatic N-methylamides and its application to molecular constructions]. | 2001 Feb |
|
Erythrocyte transketolase activity and guanidino compounds in hemodialysis patients. | 2001 Feb |
|
Apparent two-state tendamistat folding is a sequential process along a defined route. | 2001 Feb 16 |
|
Solid-phase guanidinylation as a diversification strategy of poly-L-proline type II peptide mimic scaffolds. | 2001 Feb 22 |
|
Efficient gene transfection by bisguanylated diacetylene lipid formulations. | 2001 Feb 23 |
|
Collision-induced dissociation of ring-opened cyclic depsipeptides with a guanidino group by electrospray ionization/ion trap mass spectrometry. | 2001 Jan |
|
Cellular responses of NG108-15 and SK-N-MC lines to sweet and bitter tastants as measured by extracellular acidification rates. | 2001 Jan 1 |
|
Folding-unfolding of goat alpha-lactalbumin studied by stopped-flow circular dichroism and molecular dynamics simulations. | 2001 Jan 1 |
|
The PD...(D/E)XK motif in restriction enzymes: a link between function and conformation. | 2001 Jan 16 |
|
Achieving stability and conformational specificity in designed proteins via binary patterning. | 2001 Jan 19 |
|
Probing conformational changes in the estrogen receptor: evidence for a partially unfolded intermediate facilitating ligand binding and release. | 2001 Mar |
|
Matrix proteins from insect pliable cuticles: are they flexible and easily deformed? | 2001 Mar 15 |
|
Structural alterations and inhibition of unisite and multisite ATP hydrolysis in soluble mitochondrial F1 by guanidinium chloride. | 2001 Mar 20 |
|
Dramatic stabilization of an SH3 domain by a single substitution: roles of the folded and unfolded states. | 2001 Mar 30 |
|
The pro domain of beta-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain. | 2001 Mar 30 |
|
Crystallographic and solution studies of an activation loop mutant of the insulin receptor tyrosine kinase: insights into kinase mechanism. | 2001 Mar 30 |
|
Osmolytes protect mitochondrial F(0)F(1)-ATPase complex against pressure inactivation. | 2001 Mar 9 |
|
The dimerization of folded monomers of ribulose 1,5-bisphosphate carboxylase/oxygenase. | 2001 Mar 9 |
|
Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology. | 2001 May 15 |
Sample Use Guides
Initial dosage is usually between 10 and 15 mg/kg (5 to 7 mg/pound) of body weight per day in 3 or 4 divided doses. This dosage may be gradually increased to a total daily dosage of 35 mg/kg (16 mg/pound) of body weight per day or up to the development of side effects.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2135950
Mice spinal cord neurons were treated with guanidine at concentrations between 100 nM and 100 mM. At 100 mM induced a membrane depolarization of 10 to 25 mV and rapidly and reversibly reduced GABA responses: 23.9% decrease of GABA responses was obtained with 10 mM guanidine and complete inhibition was observed with 100 mM). It also significantly reduced Glycine response at 10 mM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:39:29 UTC 2023
by
admin
on
Fri Dec 15 19:39:29 UTC 2023
|
Record UNII |
GCA2EU297U
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2119
Created by
admin on Fri Dec 15 19:39:29 UTC 2023 , Edited by admin on Fri Dec 15 19:39:29 UTC 2023
|
PRIMARY | |||
|
GCA2EU297U
Created by
admin on Fri Dec 15 19:39:29 UTC 2023 , Edited by admin on Fri Dec 15 19:39:29 UTC 2023
|
PRIMARY | |||
|
209-812-1
Created by
admin on Fri Dec 15 19:39:29 UTC 2023 , Edited by admin on Fri Dec 15 19:39:29 UTC 2023
|
PRIMARY | |||
|
Guanidine thiocyanate
Created by
admin on Fri Dec 15 19:39:29 UTC 2023 , Edited by admin on Fri Dec 15 19:39:29 UTC 2023
|
PRIMARY | |||
|
DTXSID6060478
Created by
admin on Fri Dec 15 19:39:29 UTC 2023 , Edited by admin on Fri Dec 15 19:39:29 UTC 2023
|
PRIMARY | |||
|
593-84-0
Created by
admin on Fri Dec 15 19:39:29 UTC 2023 , Edited by admin on Fri Dec 15 19:39:29 UTC 2023
|
PRIMARY | |||
|
65046
Created by
admin on Fri Dec 15 19:39:29 UTC 2023 , Edited by admin on Fri Dec 15 19:39:29 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
||
|
PARENT -> SALT/SOLVATE |
|